Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDSFEB)

• Drug Name: SI-B001 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Metastatic epithelial tumour	2D60	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMDSFEB

Molecule-Related Drug Atlas

Drug(s) Targeting Epidermal growth factor receptor (EGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Hepatocellular carcinoma	2C12.02	Approved	[3]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[4]
Gefitinib	DM15F0X	Solid tumour/cancer	2A00-2F9Z	Approved	[5]
Erlotinib	DMCMBHA	Non-small-cell lung cancer	2C25.Y	Approved	[6]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[7]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[8]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[9]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[10]
Epidermal growth factor	DMVONE6	Vulnerary	ND56.Z	Approved	[8]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[11]

Drug(s) Targeting Erbb3 tyrosine kinase receptor (Erbb-3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MM-141	DM2RJ4D	Pancreatic cancer	2C10	Phase 2	[12]
MEHD-7945A	DMHOF7T	Colorectal cancer	2B91.Z	Phase 2	[13]
Seribantumab	DMYT470	Colorectal cancer	2B91.Z	Phase 2	[14]
CDX-3379	DM5GKYD	Squamous cell carcinoma	2B60-2D01	Phase 2	[14]
MM-121	DMDJRU1	Breast cancer	2C60-2C65	Phase 2	[15]
Elisidepsin	DMB38KH	Psoriasis vulgaris	EA90	Phase 2	[16]
Sym013	DMZM6I2	Epithelial ovarian cancer	2B5D	Phase 1/2	[17]
Zenocutuzomab	DMMQGPE	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[18]
LJM716	DMGTB5N	Breast cancer	2C60-2C65	Phase 1/2	[19]
AMG888/U3-1287	DMEF4L5	Non-small-cell lung cancer	2C25.Y	Phase 1/2	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Epidermal growth factor receptor (EGFR)	TTGKNB4	EGFR_HUMAN	Not Available	[2]
Erbb3 tyrosine kinase receptor (Erbb-3)	TTDC8N2	ERBB3_HUMAN	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT04603287) A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of SystImmune.
• [3] Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
• [4] Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
• [5] Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
• [6] Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
• [7] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
• [9] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [10] Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
• [11] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [12] MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014 Feb;13(2):410-25.
• [13] Company report (Biooncology)
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] Company report (Merrimack)
• [16] Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models. Eur J Cancer. 2009 Jul;45(10):1855-64.
• [17] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [18] Clinical pipeline report, company report or official report of Merus.
• [19] An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res. 2013 Oct 1;73(19):6024-35.
• [20] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1798).